IGF1R and hepatocellular carcinoma: This was noted in hepatocellular carcinoma lines, in which resistance to anti-IGF-1R treatment was associated with increased signaling through EGFR pathways, and that this resistance was overcome by targeting both IGF-1R and EGFR [30].